IL-33-ST2 Axis in Liver Disease: Progression and Challenge

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2017 Nov 29

PMID 29180837

Citations 16

Authors

Zijian Sun

Binxia Chang

Miaomiao Gao

Jiyuan Zhang

Zhengsheng Zou

Affiliations

Soon will be listed here.

Abstract

The new member of the IL-1 family, interleukin-33 (IL-33), participates in the progression of a variety of diseases through binding with its receptor ST2. Recently, much clinical evidence and experimental data have indicated that IL-33 is associated with various liver diseases. This review primarily addresses the relationship between IL-33 and several hepatic diseases. IL-33 can alleviate high-fat diet- (HFD-) induced hepatic steatosis and insulin resistance, and IL-33 acts as an alarmin, which quickly triggers the immune system to respond to virus invasion and toxic damage to the liver. However, when liver injury is chronic, IL-33 promotes Th2 reactions and hepatic stellate cell (HSC) activity, facilitating progression to liver fibrosis. The complicated functions of IL-33 should be considered before its clinical application.

Citing Articles

The Impact of Steatotic Liver Disease on Cytokine and Chemokine Kinetics During Sepsis.

Vrsaljko N, Radmanic Matotek L, Zidovec-Lepej S, Vince A, Papic N Int J Mol Sci. 2025; 26(5).

PMID: 40076848 PMC: 11900930. DOI: 10.3390/ijms26052226.

The role of the interleukin family in liver fibrosis.

Zhang Z, Wang J, Li H, Niu Q, Tao Y, Zhao X Front Immunol. 2025; 16:1497095.

PMID: 39995661 PMC: 11847652. DOI: 10.3389/fimmu.2025.1497095.

Transgender Women with HIV Demonstrate Unique Non-Alcoholic Fatty Liver Disease Profiles.

Lake J, Hyatt A, Feng H, Miao H, Somasunderam A, Utay N Transgend Health. 2024; 9(5):413-420.

PMID: 39449788 PMC: 11496901. DOI: 10.1089/trgh.2022.0182.

Caffeine mitigates tamoxifen-induced fatty liver in Wistar rats.

Sezgin Y, Bora E, Arda D, Uyanikgil Y, Erbas O Acta Cir Bras. 2024; 39:e396924.

PMID: 39356936 PMC: 11441146. DOI: 10.1590/acb396924.

The role of interleukin-33 in organ fibrosis.

Di Carmine S, Scott M, McLean M, McSorley H Discov Immunol. 2024; 1(1):kyac006.

PMID: 38566909 PMC: 10917208. DOI: 10.1093/discim/kyac006.

References

Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan C, Ying S . IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol. 2009; 183(10):6469-77. DOI: 10.4049/jimmunol.0901575. View

Kurowska-Stolarska M, Kewin P, Murphy G, Russo R, Stolarski B, Garcia C . IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol. 2008; 181(7):4780-90. DOI: 10.4049/jimmunol.181.7.4780. View

Shimpo M, Morrow D, Weinberg E, Sabatine M, Murphy S, Antman E . Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004; 109(18):2186-90. DOI: 10.1161/01.CIR.0000127958.21003.5A. View

Yu J, Song J, Wang N, Wu Z, Zhang Q, Zhang N . Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease. Neurobiol Aging. 2010; 33(5):1014.e11-4. DOI: 10.1016/j.neurobiolaging.2010.07.003. View

Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H . Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 2009; 463(7280):540-4. DOI: 10.1038/nature08636. View

Arshad M, Patrat-Delon S, Piquet-Pellorce C, LHelgoualch A, Rauch M, Genet V . Pathogenic mouse hepatitis virus or poly(I:C) induce IL-33 in hepatocytes in murine models of hepatitis. PLoS One. 2013; 8(9):e74278. PMC: 3772926. DOI: 10.1371/journal.pone.0074278. View

Baekkevold E, Roussigne M, Yamanaka T, Johansen F, Jahnsen F, Amalric F . Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol. 2003; 163(1):69-79. PMC: 1868188. DOI: 10.1016/S0002-9440(10)63631-0. View

Peng H, Zhang Q, Li X, Liu Z, Shen J, Sun R . IL-33 Contributes to Schistosoma japonicum-induced Hepatic Pathology through Induction of M2 Macrophages. Sci Rep. 2016; 6:29844. PMC: 4956744. DOI: 10.1038/srep29844. View

Younossi Z, Gramlich T, Matteoni C, Boparai N, McCullough A . Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004; 2(3):262-5. DOI: 10.1016/s1542-3565(04)00014-x. View

10.

Weinberg E, Shimpo M, Hurwitz S, Tominaga S, Rouleau J, Lee R . Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003; 107(5):721-6. DOI: 10.1161/01.cir.0000047274.66749.fe. View

11.

Gao B, Bataller R . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011; 141(5):1572-85. PMC: 3214974. DOI: 10.1053/j.gastro.2011.09.002. View

12.

Liang Y, Jie Z, Hou L, Yi P, Wang W, Kwota Z . IL-33 promotes innate IFN-γ production and modulates dendritic cell response in LCMV-induced hepatitis in mice. Eur J Immunol. 2015; 45(11):3052-63. PMC: 4813322. DOI: 10.1002/eji.201545696. View

13.

Sakai N, Van Sweringen H, Quillin R, Schuster R, Blanchard J, Burns J . Interleukin-33 is hepatoprotective during liver ischemia/reperfusion in mice. Hepatology. 2012; 56(4):1468-78. PMC: 3465516. DOI: 10.1002/hep.25768. View

14.

Chen J, Yuan Z . Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies. Virol Sin. 2014; 29(1):17-24. PMC: 8206324. DOI: 10.1007/s12250-014-3412-3. View

15.

Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B . High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma. Transl Oncol. 2013; 6(3):311-8. PMC: 3660800. DOI: 10.1593/tlo.12418. View

16.

Friedman S . Liver fibrosis -- from bench to bedside. J Hepatol. 2003; 38 Suppl 1:S38-53. DOI: 10.1016/s0168-8278(02)00429-4. View

17.

Hayakawa H, Hayakawa M, Kume A, Tominaga S . Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007; 282(36):26369-80. DOI: 10.1074/jbc.M704916200. View

18.

Cayrol C, Girard J . IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014; 31:31-7. DOI: 10.1016/j.coi.2014.09.004. View

19.

Crockett S, Keeffe E . Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob. 2005; 4:13. PMC: 1224851. DOI: 10.1186/1476-0711-4-13. View

20.

Wong C, Leung K, Qiu H, Chow J, Choi A, Lam C . Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS One. 2012; 7(1):e29815. PMC: 3260155. DOI: 10.1371/journal.pone.0029815. View